Prognostic Value of NLRP3 Inflammasome and TLR4 Expression in Breast Cancer Patients.
NLRP3 inflammasome
PYCARD
TLR4
breast cancer
prognostic biomarker
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
05
05
2021
accepted:
17
08
2021
entrez:
20
9
2021
pubmed:
21
9
2021
medline:
21
9
2021
Statut:
epublish
Résumé
Inflammasome complexes play a pivotal role in different cancer types. NOD-like receptor protein 3 (NLRP3) inflammasome is one of the most well-studied inflammasomes. Activation of the NLRP3 inflammasome induces abnormal secretion of soluble cytokines, generating advantageous inflammatory surroundings that support tumor growth. The expression levels of the NLRP3, PYCARD and TLR4 were determined by immunohistochemistry in a cohort of primary invasive breast carcinomas (BCs). We observed different NLRP3 and PYCARD expressions in non-tumor
Identifiants
pubmed: 34540671
doi: 10.3389/fonc.2021.705331
pmc: PMC8443770
doi:
Types de publication
Journal Article
Langues
eng
Pagination
705331Informations de copyright
Copyright © 2021 Saponaro, Scarpi, Sonnessa, Cioffi, Buccino, Giotta, Pastena, Zito and Mangia.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Exp Cell Res. 2016 Mar 15;342(2):184-92
pubmed: 26968633
Pharmacogenomics. 2017 Dec;18(18):1697-1709
pubmed: 29182047
Front Immunol. 2018 Oct 08;9:2305
pubmed: 30349539
J Reprod Immunol. 2021 Apr;144:103286
pubmed: 33578174
Endocr Relat Cancer. 2019 May 09;26(6):R369-R380
pubmed: 32013374
Int J Oncol. 2018 Sep;53(3):973-986
pubmed: 30015880
BMB Rep. 2020 May;53(5):284-289
pubmed: 32317086
J Clin Oncol. 2007 Jan 1;25(1):118-45
pubmed: 17159189
Am J Transl Res. 2017 Jun 15;9(6):2723-2735
pubmed: 28670364
Oncol Rep. 2016 May;35(5):2499-515
pubmed: 26986034
Front Oncol. 2020 Sep 16;10:1683
pubmed: 33042810
Adv Sci (Weinh). 2020 Feb 14;7(6):1903616
pubmed: 32195105
Cancer Lett. 2017 Aug 1;400:137-148
pubmed: 28461245
Int J Oncol. 2018 Nov;53(5):1953-1966
pubmed: 30226596
Mol Cancer. 2018 Jan 31;17(1):18
pubmed: 29386037
Mol Med Rep. 2018 Sep;18(3):3411-3420
pubmed: 30066873
Front Oncol. 2019 Jul 02;9:588
pubmed: 31312615
BMC Cancer. 2010 Dec 03;10:665
pubmed: 21129170
J Exp Clin Cancer Res. 2018 May 2;37(1):96
pubmed: 29716631
Mol Cancer Res. 2006 Apr;4(4):221-33
pubmed: 16603636
Front Immunol. 2017 Sep 12;8:1132
pubmed: 28955343
Biochem Pharmacol. 2019 Mar;161:73-88
pubmed: 30633869
Endocr Metab Immune Disord Drug Targets. 2021;21(1):77-90
pubmed: 32901590
Cancer Lett. 2021 Jan 28;497:178-189
pubmed: 33091534
Onco Targets Ther. 2019 Aug 27;12:6927-6936
pubmed: 31695408
J Cell Biochem. 2020 Feb;121(2):1623-1634
pubmed: 31535397
Transl Oncol. 2021 Apr;14(4):101018
pubmed: 33493800
PLoS One. 2014 Oct 31;9(10):e111639
pubmed: 25360699
Am J Cancer Res. 2020 Aug 01;10(8):2582-2595
pubmed: 32905523
J Exp Med. 2001 Sep 17;194(6):863-9
pubmed: 11561001
Breast Cancer Res. 2009;11(2):R21
pubmed: 19393083
Gene. 2021 Aug 5;792:145728
pubmed: 34022297
Cell Signal. 2014 Nov;26(11):2350-7
pubmed: 25093807
Oncotarget. 2017 Jul 22;8(39):65730-65742
pubmed: 29029467
Cell Mol Life Sci. 2018 Jun;75(11):2045-2058
pubmed: 29184980
Tumour Biol. 2013 Apr;34(2):1053-9
pubmed: 23338716
Anat Rec (Hoboken). 2017 Jul;300(7):1219-1229
pubmed: 28296189
Cell Death Dis. 2019 Feb 25;10(3):193
pubmed: 30804337
BMC Cancer. 2018 Feb 27;18(1):231
pubmed: 29486738
Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2645-50
pubmed: 12598651
Int Immunol. 2005 Jan;17(1):1-14
pubmed: 15585605
Cell. 2014 May 22;157(5):1013-22
pubmed: 24855941
Cancer Immunol Res. 2017 Feb;5(2):94-99
pubmed: 28093447
J Exp Clin Cancer Res. 2017 Sep 2;36(1):116
pubmed: 28865486
Oncol Lett. 2017 Sep;14(3):3611-3615
pubmed: 28927120
J Exp Clin Cancer Res. 2017 Jun 21;36(1):81
pubmed: 28637493
Cell. 2010 Mar 19;140(6):883-99
pubmed: 20303878
Nat Rev Immunol. 2016 Jul;16(7):407-20
pubmed: 27291964
Nat Commun. 2019 Sep 26;10(1):4375
pubmed: 31558756
Breast Cancer Res. 2015 Sep 22;17:130
pubmed: 26392082
Pathol Res Pract. 2020 Jan;216(1):152737
pubmed: 31757663
Front Oncol. 2020 Sep 04;10:1587
pubmed: 33014808
Int Immunopharmacol. 2020 Nov;88:106939
pubmed: 33182039
Biochem Pharmacol. 2020 Oct;180:114186
pubmed: 32745467